{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:24:47Z","timestamp":1784849087648,"version":"3.55.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189822"],"award-info":[{"award-number":["UG1CA189822"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189828"],"award-info":[{"award-number":["UG1CA189828"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA262312"],"award-info":[{"award-number":["R01CA262312"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cct.2025.108145","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:29:14Z","timestamp":1763641754000},"page":"108145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Improving CDK4\/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CD"],"prefix":"10.1016","volume":"160","author":[{"given":"Gelareh","family":"Sadigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghai","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana F.","family":"Gareen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoRean D.","family":"Sicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"Thangarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mylin A.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio C.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne I.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth C.","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Graetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cct.2025.108145_bb0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol."},{"issue":"20","key":"10.1016\/j.cct.2025.108145_bb0010","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in advanced breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.cct.2025.108145_bb0015","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"32","key":"10.1016\/j.cct.2025.108145_bb0020","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.cct.2025.108145_bb0025","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.cct.2025.108145_bb0030","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.cct.2025.108145_bb0035","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.cct.2025.108145_bb0040","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMc1510345","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.cct.2025.108145_bb0045","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of Ribociclib and Fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cct.2025.108145_bb0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.cct.2025.108145_bb0055","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with Ribociclib plus Fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2025.108145_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.1000","article-title":"Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor\u2013positive (HR+), human epidermal growth factor receptor 2\u2013negative (HER2\u2013) advanced breast cancer (ABC): Updated analyses from PALOMA-3","volume":"39","author":"Cristofanilli","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2025.108145_bb0065","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.1001","article-title":"Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+\/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) \u00b1 ribociclib (RIB)","volume":"39","author":"Slamon","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.cct.2025.108145_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176400","article-title":"Progression-free survival and overall survival of CDK 4\/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis","volume":"21","author":"Piezzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"34","key":"10.1016\/j.cct.2025.108145_bb0075","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, Node-Positive, High-Risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"17_suppl","key":"10.1016\/j.cct.2025.108145_bb0080","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA500","article-title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: primary results from the phase III NATALEE trial","volume":"41","author":"Slamon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2025.108145_bb0085","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231178125","article-title":"Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+\/HER2- early breast cancer","volume":"15","author":"Slamon","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.cct.2025.108145_bb0090","series-title":"FDA Approves Kisqali with an Aromatase Inhibitor and Kisqali Femara Co-pack for Early High-risk Breast Cancer","year":"2024"},{"issue":"14","key":"10.1016\/j.cct.2025.108145_bb0100","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"7485","key":"10.1016\/j.cct.2025.108145_bb0105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","article-title":"30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study","volume":"330","author":"Bonadonna","year":"2005","journal-title":"BMJ"},{"issue":"Suppl. 4","key":"10.1016\/j.cct.2025.108145_bb0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1634\/theoncologist.6-suppl_4-12","article-title":"Answering patients\u2019 needs: oral alternatives to intravenous therapy","volume":"6","author":"Borner","year":"2001","journal-title":"Oncologist"},{"issue":"Suppl. 3","key":"10.1016\/j.cct.2025.108145_bb0115","first-page":"S1","article-title":"NCCN task force report: Oral chemotherapy","volume":"6","author":"Weingart","year":"2008","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.cct.2025.108145_bb0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21556660.2020.1857103","article-title":"Review of cyclin-dependent kinase 4\/6 inhibitors in the treatment of advanced or metastatic breast cancer","volume":"10","author":"Husinka","year":"2020","journal-title":"J. Drug Assess."},{"key":"10.1016\/j.cct.2025.108145_bb0125","doi-asserted-by":"crossref","first-page":"1345482","DOI":"10.3389\/fphar.2024.1345482","article-title":"Digging in real-word electronic database for assessing CDK 4\/6 inhibitors adherence in breast cancer patients from Romania","volume":"15","author":"Turcu-Stiolica","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.cct.2025.108145_bb0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10549-025-07701-x","article-title":"Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer","volume":"212","author":"Lau","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.cct.2025.108145_bb0135","author":"American Cancer Society"},{"issue":"5","key":"10.1016\/j.cct.2025.108145_bb0140","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jnci\/djz244","article-title":"Interventions to enhance adherence to oral antineoplastic agents: a scoping review","volume":"112","author":"Rosenberg","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.cct.2025.108145_bb0145","first-page":"426","article-title":"Effectiveness of mHealth apps on adherence and symptoms to oral anticancer medications: a systematic review and meta-analysis","volume":"32","author":"Chow","year":"2024","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1016\/j.cct.2025.108145_bb0150","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1111\/jan.12978","article-title":"Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study","volume":"72","author":"Kekale","year":"2016","journal-title":"J. Adv. Nurs."},{"issue":"4","key":"10.1016\/j.cct.2025.108145_bb0155","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11764-018-0682-z","article-title":"Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial","volume":"12","author":"Graetz","year":"2018","journal-title":"J. Cancer Surviv."},{"issue":"2","key":"10.1016\/j.cct.2025.108145_bb0160","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1089\/jayao.2018.0072","article-title":"Oral medication adherence among adolescents and young adults with cancer before and following use of a smartphone-based medication reminder app","volume":"8","author":"Linder","year":"2019","journal-title":"J. Adolesc. Young Adult Oncol."},{"issue":"6","key":"10.1016\/j.cct.2025.108145_bb0165","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1188\/15.ONF.647-657","article-title":"Feasibility of a text messaging intervention to promote self-management for patients prescribed oral anticancer agents","volume":"42","author":"Spoelstra","year":"2015","journal-title":"Oncol. Nurs. Forum"},{"issue":"6","key":"10.1016\/j.cct.2025.108145_bb0170","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/tmj.2015.0126","article-title":"Proof of concept of a mobile health short message service text message intervention that promotes adherence to oral anticancer agent medications: a randomized controlled trial","volume":"22","author":"Spoelstra","year":"2016","journal-title":"Telemed. J. E Health"},{"issue":"12","key":"10.1016\/j.cct.2025.108145_bb0175","article-title":"Mobile-based oral chemotherapy adherence\u2013enhancing interventions: scoping review","volume":"6","author":"Ross","year":"2018","journal-title":"JMIR Mhealth Uhealth"},{"issue":"8","key":"10.1016\/j.cct.2025.108145_bb0180","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1177\/10781552231161823","article-title":"Improving palbociclib adherence among women with metastatic breast cancer using a CONnected CUstomized Treatment Platform: a pilot study","volume":"29","author":"Sadigh","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"6","key":"10.1016\/j.cct.2025.108145_bb0185","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.17873","article-title":"Remote monitoring app for endocrine therapy adherence among patients with early-stage breast cancer: a randomized clinical trial","volume":"7","author":"Graetz","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.cct.2025.108145_bb0190","author":"Patient Advocate Foundation"},{"issue":"7","key":"10.1016\/j.cct.2025.108145_bb0195","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00005650-197807000-00001","article-title":"Access to medical care in the U.S.: realized and potential","volume":"16","author":"Andersen","year":"1978","journal-title":"Med. Care"},{"issue":"1","key":"10.1016\/j.cct.2025.108145_bb0200","first-page":"217","article-title":"Financial toxicity in cancer: predictors and associations with patient and caregiver outcomes","volume":"30","author":"Sadigh","year":"2021","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.cct.2025.108145_bb0205","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jacr.2019.07.014","article-title":"Pilot feasibility study of an oncology financial navigation program in brain cancer patients","volume":"16","author":"Sadigh","year":"2019","journal-title":"J. Am. Coll. Radiol."},{"issue":"3","key":"10.1016\/j.cct.2025.108145_bb0210","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cct.2025.108145_bb0215","author":"National Cancer Institute Community Oncology Research Program (NCORP)"},{"issue":"4","key":"10.1016\/j.cct.2025.108145_bb0220","article-title":"Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review","volume":"2","author":"Caswell-Jin","year":"2018","journal-title":"JNCI Cancer Spectr."},{"key":"10.1016\/j.cct.2025.108145_bb0225","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2147\/PPA.S249079","article-title":"Development of the NIH patient-reported outcomes measurement information system (PROMIS) medication adherence scale (PMAS)","volume":"14","author":"Peipert","year":"2020","journal-title":"Patient Prefer. Adherence"},{"issue":"Suppl. 7","key":"10.1016\/j.cct.2025.108145_bb0230","article-title":"Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Cardoso","year":"2012","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.cct.2025.108145_bb0235","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JOP.2017.023655","article-title":"Transforming practices through the oncology care model: financial toxicity and counseling","volume":"13","author":"Sherman","year":"2017","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.cct.2025.108145_bb0240","series-title":"Missing Data in Longitudinal Studies: Strategies for Bayesian Modeling and Sensitivity Analysis","author":"Daniels","year":"2008"},{"key":"10.1016\/j.cct.2025.108145_bb0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chemolab.2004.12.011","article-title":"Performance of some variable selection methods when multicollinearity is present","volume":"78","author":"Chong","year":"2005","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"10.1016\/j.cct.2025.108145_bb0250","first-page":"109","article-title":"A comparative study on some methods for handling multicollinearity problems","volume":"22","author":"Ahmad","year":"2006","journal-title":"MATEMATIKA"},{"issue":"4","key":"10.1016\/j.cct.2025.108145_bb0255","doi-asserted-by":"crossref","DOI":"10.1097\/EDE.0b013e3181caeb90","article-title":"To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health","volume":"21","author":"Hubbard","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.cct.2025.108145_bb0260","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","article-title":"RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review","volume":"7","author":"Glasgow","year":"2019","journal-title":"Front. Public Health"},{"key":"10.1016\/j.cct.2025.108145_bb0265","series-title":"Qualitative research & evaluation methods: Integrating theory and practice","author":"Patton","year":"2014"},{"key":"10.1016\/j.cct.2025.108145_bb0270","series-title":"Qualitative data analysis: An expanded sourcebook","author":"Miles","year":"1994"},{"key":"10.1016\/j.cct.2025.108145_bb0275","series-title":"Case study research: Design and methods","author":"Yin","year":"2009"},{"issue":"9","key":"10.1016\/j.cct.2025.108145_bb0280","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamainternmed.2022.3043","article-title":"Trends in remote patient monitoring use in traditional Medicare","volume":"182","author":"Tang","year":"2022","journal-title":"JAMA Intern. Med."},{"issue":"10","key":"10.1016\/j.cct.2025.108145_bb0285","first-page":"1376","article-title":"Leveraging mobile health to improve capecitabine adherence among women with breast cancer: a pilot randomized controlled trial, JCO Oncol","volume":"20","author":"Graetz","year":"2024","journal-title":"Pract"},{"issue":"11","key":"10.1016\/j.cct.2025.108145_bb0290","first-page":"1244","article-title":"Effect of a smart pill bottle and pharmacist intervention on medication adherence in patients with multiple myeloma new to lenalidomide therapy","volume":"25","author":"Mauro","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"0","key":"10.1016\/j.cct.2025.108145_bb0295","article-title":"Randomized trial of text messaging to reduce early discontinuation of adjuvant aromatase inhibitor therapy in women with early-stage breast cancer: SWOG S1105","volume":"0","author":"Hershman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2025.108145_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00015","article-title":"Bidirectional text messaging to monitor endocrine therapy adherence and patient-reported outcomes in breast cancer","volume":"1","author":"Mougalian","year":"2017","journal-title":"JCO Clin. Cancer Inform."},{"issue":"1","key":"10.1016\/j.cct.2025.108145_bb0305","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jval.2011.08.1739","article-title":"Priority symptoms in advanced breast cancer: development and initial validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast cancer Symptom Index (NFBSI-16)","volume":"15","author":"Garcia","year":"2012","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.cct.2025.108145_bb0310","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40273-016-0408-x","article-title":"Using linear equating to map PROMIS(\u00ae) Global Health items and the PROMIS-29 V2.0 profile measure to the health utilities index mark 3","volume":"34","author":"Hays","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"5 Suppl 1","key":"10.1016\/j.cct.2025.108145_bb0315","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","article-title":"The patient-reported outcomes measurement information system (PROMIS): progress of an NIH roadmap cooperative group during its first two years","volume":"45","author":"Cella","year":"2007","journal-title":"Med. Care"},{"issue":"9 Suppl 2","key":"10.1016\/j.cct.2025.108145_bb0320","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/MLR.0b013e3182631189","article-title":"Evaluating measurement equivalence across race and ethnicity on the CAHPS cultural competence survey","volume":"50","author":"Carle","year":"2012","journal-title":"Med. Care"},{"key":"10.1016\/j.cct.2025.108145_bb0325","author":"CAHPS Cancer Care Survey Measures"},{"issue":"11","key":"10.1016\/j.cct.2025.108145_bb0330","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008","volume":"63","author":"Cella","year":"2010","journal-title":"J. Clin. Epidemiol."},{"issue":"20","key":"10.1016\/j.cct.2025.108145_bb0335","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/cncr.28814","article-title":"The development of a financial toxicity patient-reported outcome in cancer: the COST measure","volume":"120","author":"de Souza","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.cct.2025.108145_bb0340","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cncr.30369","article-title":"Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive score for financial toxicity (COST)","volume":"123","author":"de Souza","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.cct.2025.108145_bb0345","series-title":"Proceedings of the Human Factors and Ergonomics Society Annual Meeting","first-page":"192","article-title":"Validation of the system usability scale (SUS) SUS in the wild","author":"Peres","year":"2013"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425003398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425003398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:41:55Z","timestamp":1781458915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425003398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":68,"alternative-id":["S1551714425003398"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.108145","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving CDK4\/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CD","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.108145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108145"}}